Correction to "Galectin-3: A novel blood test for the evaluation and management of patients with heart failure" (Reviews in Cardiovascular Medicine (2011) 12, 4, (200-210) DOI:10.3909/ricm0624);Galectin-3: A novel blood test for the evaluation and management of patients with heart failure

Reviews in Cardiovascular Medicine

Volumn 12, Issue 4, 2011, Pages 200-210

  McCullough, Peter A ^a   Olobatoke, Ariyo ^a   Vanhecke, Thomas E ^b  

^a PROVIDENCE HOSPITAL   (United States)

^b GENESYS REGIONAL MEDICAL CENTER   (United States)

Author keywords

Biomarker; Galectin 3; Heart failure; Hospitalization; Mortality; Natriuretic peptide

Indexed keywords

COLLAGEN; GALECTIN 3;

BLOOD ANALYSIS; CLINICAL EVALUATION; DISEASE COURSE; HEART FAILURE; HEART MUSCLE FIBROSIS; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; NONHUMAN; OUTPATIENT CARE; REVIEW;

EID: 84855561494     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3909/ricm131err     Document Type: Erratum

References (50)

1. Lewis T. The Harveian Oration on "CLINICAL SCIENCE". Br Med J. 1933;2:717-722.
2. McMurray JJV. What is heart failure? In: Abraham WT, Krum H, eds. Heart Failure: A Practical Approach to Treatment. New York, NY: McGraw Hill Medical; 2007:1-8.
3. Bundkirchen A, Schwinger RHG. Epidemiology and economic burden of chronic heart failure. Eur Heart J Suppl. 2004;6(suppl D):D57-D60. (Pubitemid 38993433)
4. Flaherty JD, Bax JJ, De Luca L, et al. Acute heart failure syndromes in patients with coronary artery disease: early assessment and treatment. J Am Coll Cardiol. 2009;53:254-263.
5. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol. 2009;53: 557-573.
6. Velagaleti RS, Vasan RS. Epidemiology of heart failure. In: Mann DL, ed. heart failure: A Companion to Braunwald's Heart Disease. 2nd ed. Saint Louis, MO: Elsevier; 2011:346-354.
7. Vasquez C, Benamer N, Morley GE. The cardiac fibroblast: functional and electrophysiological considerations in healthy and diseased heart. J Cardiovasc Pharmacol. 2011;57:380-388.
8. American Heart Association. Heart Disease and Stroke Statistics - 2006 Update. Dallas, TX: American Heart Association; 2006.
9. McCullough PA, Philbin EF, Spertus JA, et al. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol. 2002;39:60-69. (Pubitemid 34059862)
10. Cavalcante JL, Lima JA, Redheuil A, Al-Mallah MH. Aortic stiffness: current understanding and future directions. J Am Coll Cardiol. 2011;57:1511-1522.
11. Soman P, Lahiri A, Mieres JH, et al. Etiology and pathophysiology of new-onset heart failure: evaluation by myocardial perfusion imaging. J Nucl Cardiol. 2009;16:82-91.
12. van den Borne SW, Diez J, Blankesteijn WM, et al. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol. 2010;7:30-37.
13. Felker GM, Shaw LK, O'Conner CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol. 2002;39:210-218.
14. Michels VV, Moll PP, Miller FA, et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med. 1992;326:77-82.
15. Hutchinson KR, Stewart JA Jr, Lucchesi PA. Extracellular matrix remodeling during the progression of volume overload-induced heart failure. J Mol Cell Cardiol. 2010;48:564-569.
16. Vanhecke TE, Kim R, Raheem SZ, McCullough PA. Myocardial ischemia in patients with diastolic dysfunction and heart failure. Curr Cardiol Rep. 2010;12:216-222.
17. Fonarow GC, Abraham WT, Albert NM, et al OPTIMIZE-HF Investigators and Hospitals. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA. 2007;297:61-70. (Pubitemid 46041727)
18. Khand AU, Gemmell I, Rankin AC, Cleland JG. Clinical events leading to the progression of heart failure: insights from a national database of hospital discharges. Eur Heart J. 2001;22:153-164. (Pubitemid 32619637)
19. McCullough PA, Khandelwal AK, McKinnon JE, et al. Outcomes and prognostic factors of systolic as compared with diastolic heart failure in urban America. Congest Heart Fail. 2005;11:6-11.
20. Creemers EE, Pinto YM. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res. 2011;89:265-272.
21. Cooper DN. Galectinomics: finding themes in complexity. Biochim Biophys Acta. 2002;1572:209-231. (Pubitemid 35246346)
22. Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006;1760:616-635.
23. Krześlak A, Lipińska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett. 2004;9: 305-328. (Pubitemid 38902225)
24. Ochieng J, Platt D, Tait L, et al. Structure-function relationship of a recombinant human galactoside-binding protein. Biochemistry. 1993;32: 4455-4460. (Pubitemid 23137756)
25. Nachtigal M, Al-Assaad Z, Mayer EP, et al. Galectin-3 expression in human atherosclerotic lesions. Am J Pathol. 1998;152:1199-1208. (Pubitemid 28221873)
26. Raimond J, Zimonjic DB, Mignon C, et al. Mapping of the galectin-3 gene (LGALS3) to human chromosome 14 at region 14q21-22. Mamm Genome. 1997;8:706-707. (Pubitemid 28060633)
27. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev. 2009;230:160-171.
28. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110:3121-3128. (Pubitemid 39492008)
29. Liu YH, D'Ambrosio M, Liao TD, et al. N-acetylseryl-aspartyl-lysyl- proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growthregulatory lectin. Am J Physiol Heart Circ Physiol. 2009;296:H404-H412.
30. de Boer RA, Van Veldhuisen DJ, Gansevoort RT, et al. Galectin-3, cardiovascular risk factors, and outcome in the general population. Paper presented at: 12th Annual Congress of the European Society of Cardiology; Aug. 27-31, 2011; Paris, France.
31. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48:1217-1224. (Pubitemid 44345127)
32. Milting H, Ellinghaus P, Seewald M, et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant. 2008;27:589-596. (Pubitemid 351715387)
33. Lok DJ, Van Der Meer P, de la Porte PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010;99:323-328.
34. Lin YH, Lin LY, Wu YW, et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta. 2009;409:96-99.
35. de Boer RA, Lok DJ, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43:60-68.
36. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002;106:416-422. (Pubitemid 34803684)
37. Safley DM, McCullough PA. The emerging role of brain natriuretic peptide in the management of acute and chronic heart failure in outpatients. Heart Fail Monit. 2003;4:13-20.
38. Gallagher MJ, McCullough PA. The emerging role of natriuretic peptides in the diagnosis and treatment of decompensated heart failure. Curr Heart Fail Rep. 2004;1:129-135.
39. Kociol RD, Pang PS, Gheorghiade M, et al. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol. 2010;56:1071-1078.
40. BGM Galectin-3 [package insert]. Waltham, MA, BG Medicine, Inc; 2010.
41. Chinnaiyan KM, Alexander D, Maddens M, McCullough PA. Curriculum in cardiology: integrated diagnosis and management of diastolic heart failure. Am Heart J. 2007;153:189-200. (Pubitemid 46096853)
42. Chinnaiyan KM, Alexander D, McCullough PA. Role of angiotensin II in the evolution of diastolic heart failure. J Clin Hypertens (Greenwich). 2005;7:740-747.
43. Zile MR, DeSantis SM, Baicu CF, et al. Plasma galectin-3 levels in patients with structural and clinical manifestations of hypertensive heart disease: relationship to determinants of matrix composition. Circulation. 2010;122:A12433.
44. Shah RV, Chen-Tournoux AA, Picard MH, et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010;12:826-832.
45. Shenkman HJ, Pampati V, Khandelwal AK, et al. Congestive heart failure and QRS duration: establishing prognosis study. Chest. 2002;122:528-534. (Pubitemid 35002131)
46. Grandin EW, Cannon CP, Jarolim P, et al. Galectin-3 and the development of heart failure after acute coronary syndrome: a pilot experience from PROVE IT-TIMI 22. J Am Coll Cardiol 2011;57:E1024.
47. Tang WH, Shrestha K, Shao Z, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol. 2011;108:385-390.
48. Ueland T, Aukrust P, Broch K, et al. Galectin-3 in heart failure: high levels are associated with all-cause mortality. Int J Cardiol. 2011;150:361-364.
49. Smith A, Wu AH, Abel G, et al. Analytical performance of an optimized ELISA for galectin-3. Clin Chem. 2009;55:B69.
50. Muntendam P, Adourian A, Christenson R. Reference interval for plasma galectin-3 in healthy subjects age 55 years and older. Clin Chem. 2009;55:B72.